Results 101 to 110 of about 3,887,212 (164)

Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment. [PDF]

Arch Endocrinol Metab, 2022
Ataei-Nakhaei S, Aryana K, Mostafavi SM, Kosari HM, Esmatinia M, Aghaee A.   +5 more
europepmc   +1 more source

Peptide Receptor Radionuclide Therapy-Induced Hepatotoxicity in Patients With Metastatic Neuroendocrine Tumors.

, 2015
BACKGROUND Treatment of metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) with peptide receptor radionuclide therapy (PRRT) is effective in retarding tumor growth.
Yang YX, Teitelbaum UR, Wild D, Soulen MC, Metz DC, Bennett B, Pryma DA, Nicolas G, Riff BP   +8 more
core   +1 more source

Peptide receptor radionuclide therapy for metastatic paragangliomas

, 2016
There is little evidence to direct the management of malignant paragangliomas (mPGL) beyond initial surgical treatment. Peptide receptor radionuclide therapy (PRRT), using somatostatin analogues, is effective in other neuroendocrine tumours, but data on ...
Pinato, DJ, Black, JRM, Tan, TM, Adjogatse, D, Ramaswami, R, Sharma, R   +5 more
core   +2 more sources

Survival predictors of ¹⁷⁷Lu-Dotatate peptide receptor radionuclide therapy (PRRT) in patients with progressive well-differentiated neuroendocrine tumors (NETS). [PDF]

J Cancer Res Clin Oncol, 2022
Swiha MM, Sutherland DEK, Sistani G, Khatami A, Abazid RM, Mujoomdar A, Wiseman DP, Romsa JG, Reid RH, Laidley DT.   +9 more
europepmc   +1 more source

Treatment of Gastroenteropancreatic Neuroendocrine Tumors with Peptide Receptor Radionuclide Therapy

, 2013
The primary treatment of gastroenteropancreatic neuroendocrine tumors (GEPNETs) is surgery with curative intent or debulking of the tumor mass. In case of metastatic disease, cytoreductive options are limited.
Krenning, Eric, Vliet, Esther, Jong, Marion, Teunissen, Jaap, Kwekkeboom, Dik, Kam, BLR   +5 more
core   +1 more source

Peptide Receptor Radionuclide Therapy (PRRT) with ¹⁷⁷Lu-DOTATATE; Differences in Tumor Dosimetry, Vascularity and Lesion Metrics in Pancreatic and Small Intestinal Neuroendocrine Neoplasms. [PDF]

Cancers (Basel), 2021
Jahn U, Ilan E, Sandström M, Lubberink M, Garske-Román U, Sundin A.   +5 more
europepmc   +1 more source

Peptide Receptor Radionuclide Therapy versus Capecitabine/Temozolomide for the Treatment of Metastatic Pancreatic Neuroendocrine Tumors

Background: Peptide Receptor Radionuclide Therapy (PRRT), a form of Radioligand Therapy (RLT), and Capecitabine/Temozolomide (CAPTEM) are cornerstones of systemic therapy for metastatic pancreatic neuroendocrine tumors (PNETs). Data regarding comparative
Chih-Yi Liao, Joseph Tobias, Xavier M. Keutgen, Rushabh Gujarathi, Sara Abou Azar   +4 more
core   +1 more source

Parapharyngeal space meningioma

Radiology Case Reports
Parapharyngeal space (PPS) meningiomas are rare extracranial tumors that can mimic more common PPS lesions. We report a case of a 23-year-old female who presented with a painless, progressive neck swelling and intraoral bulge.
Pranjal Rai, MD, Niyati Pokar, MBBS, Animesh Awadhiya, MBBS, Joe Joseph, MD, Dhairya A Lakhani, MD   +4 more
doaj   +1 more source

Success of 177Lu-DOTATATE therapy in a metastatic pituitary neuroendocrine tumor

Endocrine Oncology
Metastatic pituitary neuroendocrine tumors (PitNETs) are rare and often aggressive. Patients should be evaluated for metastatic disease when their biochemical presentation is discordant with pituitary tumor burden or when they present with non-pituitary,
Katherine I Wolf, Zhonglin Lu, Elizabeth A Hesseltine, Ka-Kit Wong, Francis P Worden, Tobias Else   +5 more
doaj   +1 more source

Case report: Resolution of VIPoma-related symptoms with peptide receptor radionuclide therapy

Frontiers in Oncology
Peptide receptor radionuclide therapy (PRRT) is used for the management of neuroendocrine tumors (NETs) not responsive to somatostatin analogs. In this case series, we report two patients with pancreatic vasoactive intestinal peptide (VIP)-secreting NETs
Turgut Bora Cengiz, Raksha Kulkarni, Virginia Corbett, Nasrin V. Ghesani, Edward Wolin, Munir V. Ghesani   +5 more
doaj   +1 more source